Skip to content
Pipeline

Therapeutic Candidates

Programs
Early Discovery E Disc
Late Discovery L Disc
Lead Optimization L Opt
IND-Enabling IND
Clinical Clin
Oncology
Programs: IBIO-101

This IL-2-sparing anti-CD25 antibody aims to reduce tumor growth by selectively depleting immunosuppressive regulatory T cells without affecting cancer-killing effector T cells. It’s being investigated as a fast follower to Hoffman-La Roche’s RG6292 molecule, with potential indications including solid tumors, hairy cell leukemia, lymphoma, and head and neck cancers.

LEARN MORE

Programs: Trop-2 x CD3*

TROP-2 (Trophoblast cell-surface antigen 2) is an overexpressed cell surface protein in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers. It plays a crucial role in promoting tumor growth, survival, and metastasis by regulating cell signaling pathways, adhesion, and epithelial-mesenchymal transition. Targeting TROP-2 with bispecific antibodies aims to engage the immune system to treat TROP-2-positive cancers selectively and effectively.

Learn More

Programs: MUC16

MUC16 is a tumor-associated epitope that is over-expressed and shed by tumor cells, making it difficult to kill the tumor. The antibody being investigated binds to nearby epitopes that are not shed to maintain activity against the tumor.

Learn More

Programs: Target 5
Immuno-Oncology
Programs: EGFRvIII

This anti-EGFRvIII antibody is being investigated to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue. The novel antibody has high antibody-dependent cellular cytotoxicity (ADCC), potentially reducing toxicity and expanding the therapeutic window.

LEARN MORE

Programs: CCR8

This potential candidate is designed to selectively bind to CCR8, a protein highly expressed by regulatory T cells in the tumor microenvironment, without killing its closely related neighbor, CCR4. When CCR8 and regulatory T cells are depleted without killing CCR4, CCR4 triggers an innate immune response to selectively target and kill tumors. This target can potentially treat a broad range of cancers, alone and in combination with checkpoint inhibitors.

LEARN MORE

Programs: Target 8
Immuno-Oncology
NIAID Partnership
Programs: Lassa Virus

In collaboration with the National Institute of Allergy and Infectious Diseases, which is a component of the National Institutes of Health, iBio is investigating the potential of a vaccine for Lassa fever, a sometimes-fatal viral disease endemic to West Africa for which there are no current vaccines. The partnership is evaluating whether iBio’s Drug Discovery Platform can steer immunity toward specific epitopes, or binding sites, generating a stronger immune response, and offer advantages over current vaccine development approaches.

* Developed with EngageTx bispecific platform

iBio’s technology stack is designed to deliver next-generation precision antibodies for difficult targets and modes of action with the potential for high developability and enhanced safety. Powered by machine learning, our platform combines epitope steering, antibody optimization for monoclonal antibodies and CD3 T-cell engager bispecfics, and antibody masking, to overcome key challenges in discovery and development.

Our team of computational biologists and highly skilled drug hunters are engineering antibodies for hard-to-drug targets to support rapid pipeline growth and maturation. We have a pipeline of 7 biologics, primarily focused on immuno-oncology. Driven by our commitment to innovation, we are developing select programs internally while maintaining the flexibility to explore collaborative opportunities through licensing our programs to strategic partners.

We are excited about the potential therapeutic benefits of our proprietary pipeline and are looking for partners who share our passion for bringing innovative treatments to advance healthcare and improve patient lives.

To learn more about our pipeline candidates and potential partnership opportunities, please contact us.

Top